(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today following remarks by Food and Drug Administration Commissioner Scott Gottlieb: “Manufacturers have chosen to negotiate price concessions with pharmacy benefit managers (PBMs) using rebates, which are
PBM Tools PBM Tools Will Save Health Plan Sponsors and Consumers More than $1 Trillion on Prescription Drug Costs As prescription drug spending continues to increase, research shows PBMs’ cost savings and patient care management tools should reduce prescription drug
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
PBMs Support and Encourage Biosimilar Competition Increased biosimilar competition drives down prescription drug costs Having multiple biosimilar and reference biologic competitor products with equivalent patient benefits on the market allows pharmacy benefit companies, PBMs, to push manufacturers to compete on
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
©2024 PCMA. All Rights Reserved.
